Literature DB >> 25962438

Chronic relapsing remitting Sweet syndrome--a harbinger of myelodysplastic syndrome.

Austin G Kulasekararaj1,2, Shahram Kordasti1,2, Tanya Basu2,3, Jonathan R Salisbury4, Ghulam J Mufti1,2, Anthony W P du Vivier3.   

Abstract

Sweet syndrome (SS) is an acute febrile neutrophilic dermatosis. It has been associated with malignant disease, especially acute myeloid leukaemia (AML), infections, autoimmune disorders and drugs, particularly granulocyte colony-stimulating factor (GCSF). No cause is found in the rest, which are labelled idiopathic. We describe 15 patients with SS, which we believe represent 'immune dysregulation' secondary to myelodysplastic syndrome (MDS). We initially identified 31 patients with SS in a cohort of 744 patients with MDS and 215 with AML seen over a 6-year period (2004-10). The cause in 16 patients could be attributed either to administration of GCSF or chemotherapy. The eruption was brief and resolved spontaneously or following withdrawal of GCSF. Fifteen patients however, had a chronic debilitating illness dominated by the skin eruptions. Diagnosis of chronic relapsing SS was delayed because the pathology was not always typical of classical neutrophil-rich SS and included lymphocytic and histiocytoid infiltrates and bone marrow was not always performed because the relevance of the eruption to MDS was often not immediately appreciated. All these patients had 'low risk' MDS, diagnosed at a median of 17 months (range 0-157) following the diagnosis of SS. We describe a chronic debilitating episodic clinically distinctive skin eruption with features of SS but not always definitive histopathology often associated with immunological abnormalities affecting other systems related to underlying low risk MDS.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  5-azacytidine; Sweet syndrome; autoimmunity; myelodysplastic syndrome

Mesh:

Substances:

Year:  2015        PMID: 25962438     DOI: 10.1111/bjh.13485

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  8 in total

1.  Clinicopathologic, Immunohistochemical, and Molecular Features of Histiocytoid Sweet Syndrome.

Authors:  Victoria Alegría-Landa; Socorro María Rodríguez-Pinilla; Angel Santos-Briz; José Luis Rodríguez-Peralto; Victor Alegre; Lorenzo Cerroni; Heinz Kutzner; Luis Requena
Journal:  JAMA Dermatol       Date:  2017-07-01       Impact factor: 10.282

Review 2.  Sweet's syndrome associated with clonal hematopoiesis of indeterminate potential responsive to 5-azacitidine.

Authors:  George Yaghmour; Eric Wiedower; Bassam Yaghmour; Sara Nunnery; Eric Duncavage; Mike G Martin
Journal:  Ther Adv Hematol       Date:  2016-11-29

3.  [Bullous Sweet's syndrome with pulmonary involvement].

Authors:  A Sesti; K Rappersberger; C Posch
Journal:  Hautarzt       Date:  2017-08       Impact factor: 0.751

4.  Successful Treatment of Syndrome of Inappropriate Antidiuretic Hormone Secretion Associated with Neuro-Sweet Disease in Myelodysplastic Syndrome.

Authors:  Satoko Oka; Kazuo Ono; Masaharu Nohgawa
Journal:  Intern Med       Date:  2017-12-08       Impact factor: 1.271

Review 5.  Insights Into the Pathogenesis of Sweet's Syndrome.

Authors:  Michael S Heath; Alex G Ortega-Loayza
Journal:  Front Immunol       Date:  2019-03-12       Impact factor: 7.561

Review 6.  Autoimmune Complications in Hematologic Neoplasms.

Authors:  Wilma Barcellini; Juri Alessandro Giannotta; Bruno Fattizzo
Journal:  Cancers (Basel)       Date:  2021-03-26       Impact factor: 6.639

7.  Chronic idiopathic Sweet syndrome: A report of 2 cases.

Authors:  Asha Gowda; Misha A Rosenbach; Robert G Micheletti; William D James
Journal:  JAAD Case Rep       Date:  2016-05-31

Review 8.  Immune-Mediated Dermatoses in Patients with Haematological Malignancies: A Comprehensive Review.

Authors:  Roberto Maglie; Giovanni Genovese; Farzan Solimani; Alba Guglielmo; Alessandro Pileri; Francesca Portelli; Michael Hertl; Angelo Valerio Marzano; Emiliano Antiga
Journal:  Am J Clin Dermatol       Date:  2020-12       Impact factor: 7.403

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.